237 related articles for article (PubMed ID: 29921200)
1. Different Targeting Strategies for Treating Breast Cancer Bone Metastases.
Irshad I; Varamini P
Curr Pharm Des; 2018; 24(28):3320-3331. PubMed ID: 29921200
[TBL] [Abstract][Full Text] [Related]
2. [Anti-RANKL antibody for the management of bone metastasis].
Yoneda T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
4. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Coleman RE
Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.
Buijs JT; Kuijpers CC; van der Pluijm G
Curr Pharm Des; 2010; 16(27):3015-27. PubMed ID: 20722621
[TBL] [Abstract][Full Text] [Related]
6. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
Takahashi S
Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
[TBL] [Abstract][Full Text] [Related]
7. The role of bisphosphonates in breast and prostate cancers.
Brown JE; Neville-Webbe H; Coleman RE
Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for treatment of breast cancer bone metastases and beyond.
Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
10. Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.
Hiraga T
Expert Opin Investig Drugs; 2016; 25(3):319-34. PubMed ID: 26778342
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of bone metastases in breast cancer patients--an update.
Jacobs C; Simos D; Addison C; Ibrahim M; Clemons M
Expert Opin Pharmacother; 2014 Jun; 15(8):1109-18. PubMed ID: 24673572
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targets for bone metastases in breast cancer.
Clézardin P
Breast Cancer Res; 2011 Apr; 13(2):207. PubMed ID: 21586099
[TBL] [Abstract][Full Text] [Related]
13. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
14. Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Suvannasankha A; Chirgwin JM
Breast Cancer Res; 2014; 16(6):484. PubMed ID: 25757219
[TBL] [Abstract][Full Text] [Related]
15. [Encounter of cancer cells with bone. Development of bone metastasis-specific targeting therapy].
Hayashi S; Hanamura T
Clin Calcium; 2011 Mar; 21(3):389-96. PubMed ID: 21358060
[TBL] [Abstract][Full Text] [Related]
16. Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer.
Coleman RE
Oncology (Williston Park); 2016 Aug; 30(8):695-702. PubMed ID: 27528238
[TBL] [Abstract][Full Text] [Related]
17. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
[TBL] [Abstract][Full Text] [Related]
18. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of breast cancer metastases to bone.
Guise TA; Kozlow WM; Heras-Herzig A; Padalecki SS; Yin JJ; Chirgwin JM
Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S46-53. PubMed ID: 15807924
[TBL] [Abstract][Full Text] [Related]
20. Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling.
Hsieh CJ; Kuo PL; Hou MF; Hung JY; Chang FR; Hsu YC; Huang YF; Tsai EM; Hsu YL
Int J Oncol; 2015 Feb; 46(2):555-62. PubMed ID: 25421824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
